SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion.
Accepted version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Abstract
The SARS-CoV-2 B.1.617 variant emerged in the Indian state of Maharashtra in late 2020. There have been fears that 2 key mutations seen in the receptor-binding domain, L452R and E484Q, would have additive effects on evasion of neutralizing antibodies. We report that spike bearing L452R and E484Q confers modestly reduced sensitivity to BNT162b2 mRNA vaccine-elicited antibodies following either first or second dose. The effect is similar in magnitude to the loss of sensitivity conferred by L452R or E484Q alone. These data demonstrate reduced sensitivity to vaccine-elicited neutralizing antibodies by L452R and E484Q but lack of synergistic loss of sensitivity.
Description
Keywords
B.1.617, COVID-19, Indian variant, SARS-CoV-2, antibody escape, evasion, fitness, infectivity, neutralizing antibodies, resistance, spike mutation, Angiotensin-Converting Enzyme 2, Animals, Antibodies, Neutralizing, Antibodies, Viral, BNT162 Vaccine, COVID-19, COVID-19 Vaccines, Chlorocebus aethiops, HEK293 Cells, Humans, Immune Evasion, India, Mutation, Protein Binding, SARS-CoV-2, Serine Endopeptidases, Spike Glycoprotein, Coronavirus, Vero Cells
Journal Title
J Infect Dis
Conference Name
Journal ISSN
0022-1899
1537-6613
1537-6613
Volume Title
224
Publisher
Oxford University Press (OUP)
Publisher DOI
Rights
All rights reserved
Sponsorship
Wellcome Trust (108082/A/15/Z)
Rosetrees Trust (M957)
Addenbrooke's Charitable Trust (ACT) (900296)
Rosetrees Trust (M957)
Addenbrooke's Charitable Trust (ACT) (900296)